摘要
乙肝相关性肝病肝移植患者术后乙型肝炎病毒再感染是影响其长期存活的主要因素,因此,有效地防治HBV再感染或者乙肝复发,是我国肝移植受者术后长期存活的关键。术前应用抗乙肝病毒药物,使血液中HBV DNA处于检测不到水平,以及术中使用高效价人乙肝免疫球蛋白,术后联合应用核苷类药物,保持抗-HBs水平大于100IU/L～150IU/L,可以达到长期有效预防HBV感染防止乙肝复发的目的。
Re-infection is the main factor affecting the long-term survival for Hepatitis B-related liver disease after liver transplantation（LT） in patients with hepatitis B Virus（HBV）. Therefore, effectively prevent and treat HBV re--infection or recurrence of hepatitis B is the key to a long--term survival for liver transplant recipients in China. Preoperative anti-- HBV drugs for the undetectable levels of HBV DNA in blood, and the intraoperative use of high titer of hepatitis B immunoglobulin （ HBIG）, and HBIG plus the same nucleotide drugs after LT to maintain anti-- HBs levels greater than 100-- 150 IU/L, can achieve the purpose for the long--term effective preventing HBV infection or hepatitis B recurrence.
出处
《医学与哲学（B）》
2011年第11期15-18,44,共5页
Medicine & Philosophy(B)
关键词
乙型肝炎
肝移植
复发
再感染
hepatitis B, liver transplantation, recurrence, re--infection
